ReP USP - Resultado da busca

Artigo de periodico
CB1 receptor silencing attenuates Ketamine-induced hyperlocomotion without compromising its antidepressant-like effects (2023)
Nunes, Pedro Henrique Gobira; LaMar, Jacob; Marques, Jade dos Santos; Sartim, Ariandra Guerini ; Silveira, Kennia Moura ; Santos, Luana; Wegener, Gregers; Guimarães, Francisco Silveira ; Mackie, Ken; Lu, Hui-Chen; Joca, Sâmia Regiane Lourenço
Source: Cannabis and Cannabinoid Research. Unidades: FMRP, FCFRP, FCF
Subjects: ANTIDEPRESSIVOS, ESTIMULANTES DO SISTEMA NERVOSO CENTRAL, CANABINOIDES, CAMUNDONGOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NUNES, Pedro Henrique Gobira et al. CB1 receptor silencing attenuates Ketamine-induced hyperlocomotion without compromising its antidepressant-like effects. Cannabis and Cannabinoid Research, v. 8, n. 5, p. 768-778, 2023Tradução . . Disponível em: https://doi.org/10.1089/can.2022.0072. Acesso em: 05 jan. 2026.
APA
Nunes, P. H. G., LaMar, J., Marques, J. dos S., Sartim, A. G., Silveira, K. M., Santos, L., et al. (2023). CB1 receptor silencing attenuates Ketamine-induced hyperlocomotion without compromising its antidepressant-like effects. Cannabis and Cannabinoid Research, 8( 5), 768-778. doi:10.1089/can.2022.0072
NLM
Nunes PHG, LaMar J, Marques J dos S, Sartim AG, Silveira KM, Santos L, Wegener G, Guimarães FS, Mackie K, Lu H-C, Joca SRL. CB1 receptor silencing attenuates Ketamine-induced hyperlocomotion without compromising its antidepressant-like effects [Internet]. Cannabis and Cannabinoid Research. 2023 ; 8( 5): 768-778.[citado 2026 jan. 05 ] Available from: https://doi.org/10.1089/can.2022.0072
Vancouver
Nunes PHG, LaMar J, Marques J dos S, Sartim AG, Silveira KM, Santos L, Wegener G, Guimarães FS, Mackie K, Lu H-C, Joca SRL. CB1 receptor silencing attenuates Ketamine-induced hyperlocomotion without compromising its antidepressant-like effects [Internet]. Cannabis and Cannabinoid Research. 2023 ; 8( 5): 768-778.[citado 2026 jan. 05 ] Available from: https://doi.org/10.1089/can.2022.0072
Artigo de periodico
Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects (2021)
Sartim, Ariandra Guerini; Marques, J.; Silveira, Kennia Moura; Nunes, Pedro Henrique Gobira; Guimarães, Francisco Silveira ; Wegener, G.; Wegener, Sâmia Regiane Lourenço Joca
Source: Neuropharmacology. Unidades: FMRP, FCFRP
Subjects: ANTIDEPRESSIVOS, COMPORTAMENTO ANIMAL, CANABINOIDES, DEPRESSÃO, HIPOCAMPO, ATIVIDADE MOTORA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SARTIM, Ariandra Guerini et al. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects. Neuropharmacology, v. 195, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2021.108679. Acesso em: 05 jan. 2026.
APA
Sartim, A. G., Marques, J., Silveira, K. M., Nunes, P. H. G., Guimarães, F. S., Wegener, G., & Wegener, S. R. L. J. (2021). Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects. Neuropharmacology, 195. doi:10.1016/j.neuropharm.2021.108679
NLM
Sartim AG, Marques J, Silveira KM, Nunes PHG, Guimarães FS, Wegener G, Wegener SRLJ. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects [Internet]. Neuropharmacology. 2021 ; 195[citado 2026 jan. 05 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108679
Vancouver
Sartim AG, Marques J, Silveira KM, Nunes PHG, Guimarães FS, Wegener G, Wegener SRLJ. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects [Internet]. Neuropharmacology. 2021 ; 195[citado 2026 jan. 05 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108679
Artigo de periodico
Effects of doxycycline in swiss mice predictive models of schizophrenia (2020)
Pereira, Ana Carolina de Castro Issy; Pedrazzi, João Francisco Cordeiro; Oosten, Anna Beatriz Saito van; Checheto, Thiago; Silva, Rafaela R.; Noël, François; Del Bel, Elaine Aparecida
Source: Neurotoxicity Research. Unidades: FCFRP, FORP, FMRP
Subjects: ESQUIZOFRENIA, MODELOS ANIMAIS, FARMACOLOGIA, ANTIPSICÓTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEREIRA, Ana Carolina de Castro Issy et al. Effects of doxycycline in swiss mice predictive models of schizophrenia. Neurotoxicity Research, v. 38, n. 4, p. 1049-1060, 2020Tradução . . Disponível em: https://doi.org/10.1007/s12640-020-00268-z. Acesso em: 05 jan. 2026.
APA
Pereira, A. C. de C. I., Pedrazzi, J. F. C., Oosten, A. B. S. van, Checheto, T., Silva, R. R., Noël, F., & Del Bel, E. A. (2020). Effects of doxycycline in swiss mice predictive models of schizophrenia. Neurotoxicity Research, 38( 4), 1049-1060. doi:10.1007/s12640-020-00268-z
NLM
Pereira AC de CI, Pedrazzi JFC, Oosten ABS van, Checheto T, Silva RR, Noël F, Del Bel EA. Effects of doxycycline in swiss mice predictive models of schizophrenia [Internet]. Neurotoxicity Research. 2020 ; 38( 4): 1049-1060.[citado 2026 jan. 05 ] Available from: https://doi.org/10.1007/s12640-020-00268-z
Vancouver
Pereira AC de CI, Pedrazzi JFC, Oosten ABS van, Checheto T, Silva RR, Noël F, Del Bel EA. Effects of doxycycline in swiss mice predictive models of schizophrenia [Internet]. Neurotoxicity Research. 2020 ; 38( 4): 1049-1060.[citado 2026 jan. 05 ] Available from: https://doi.org/10.1007/s12640-020-00268-z

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Funding Agencies

Indexado em